Alprostadil (Caverject/MUSE) Adolescent (Ages 12 to 17) Dosing

The direct answer: no adolescent dose has been established

The most important fact on this page is also the simplest: the FDA-approved prescribing information does not provide an alprostadil dosing regimen for erectile dysfunction in patients ages 12 to 17.

The current Caverject label states that safety and effectiveness have not been established in pediatric patients. Its patient information says the product is not meant for children [1]. The current MUSE label likewise says that the intraurethral product is not indicated for newborns or children [3]. Caverject Impulse is another intracavernosal alprostadil presentation; its labeling also places pediatric use outside the established evidence base [2].

That means there is no evidence-backed adolescent starting dose, titration increment, home-use frequency, or maximum dose that a general educational article can responsibly provide. Online figures such as a 1.25 mcg starting dose, fixed titration steps, or an age-based ceiling are not established pediatric regimens [1][2][4]. A number copied or scaled from the adult label remains an adult number.

Adolescent erectile symptoms require a diagnosis before a drug

Erectile symptoms in an adolescent do not automatically mean the same disease process seen in an older adult. A 2024 review written for pediatric urologists describes erectile dysfunction in adolescents and young adults as an increasingly encountered problem that requires a dedicated evaluation, work-up, and treatment approach [4]. The purpose of that evaluation is to identify what is actually causing the symptom before choosing a therapy.

Possible contributors can span several categories:

• situational anxiety, depression, trauma, relationship stress, or other psychosocial factors;
• medication or substance effects;
• endocrine, neurologic, vascular, or structural conditions;
• consequences of pelvic or urologic surgery, injury, or congenital disease;
• pain, curvature, priapism history, or another penile condition;
• inaccurate expectations about normal sexual response.

The review does not turn alprostadil into a routine adolescent treatment. Instead, it supports specialist assessment in a population where developmental context, privacy, consent, safeguarding, and the medical differential diagnosis all matter [4].

What off-label use means and what it does not mean

“Off-label” describes use of an approved medication in a way that is not included in its FDA-approved labeling, such as a different age group or indication. It does not automatically mean that a prescription is improper. The American Academy of Pediatrics explains that pediatric off-label use can be appropriate when a clinician uses professional judgment and the best available evidence for an individual patient [5]. The FDA similarly explains that clinicians may prescribe an approved drug for an unapproved use when they judge it medically appropriate [6].

But off-label use does not create missing evidence. It does not establish a universal adolescent dose, guarantee effectiveness, or erase the warnings in the label. It also does not mean an adolescent or family should reproduce an adult protocol without a clinician.

For alprostadil, an individualized off-label decision still must explain why the drug is being considered, which exact formulation is proposed, where titration and training will occur, and how prolonged erection, bleeding, pain, or treatment failure will be handled.

The three products are not interchangeable

Alprostadil is available in different formulations and presentations. Their labeled adult instructions cannot be substituted for one another, and none supplies a pediatric dosing table.

• Caverject vial: a powder reconstituted for intracavernosal injection. The adult label lists 20 mcg and 40 mcg single-dose vials, office-based first injections, and doses above 60 mcg as not recommended [1].
• Caverject Impulse: a dual-chamber injection device with different strengths, dose increments, preparation, and storage instructions [2]. Package strength is not the administered dose.
• MUSE: an intraurethral system rather than an injection. Current labeling describes 250, 500, and 1,000 mcg systems and an adult in-office titration process; it is not indicated for children [3].

Confusing these products can cause a large dosing error. Any prescription must name the exact product, presentation, strength, route, and administration instructions.

What the adult evidence can and cannot establish

There is a legitimate adult evidence base for alprostadil. Controlled and comparative studies have evaluated intracavernosal alprostadil, transurethral alprostadil, and their longer-term use in adult men with erectile dysfunction [10][11][12][13]. EDEX, another FDA-labeled intracavernosal alprostadil product, also states that safety and effectiveness have not been established in pediatric patients [9].

Those sources can support adult efficacy and known adult adverse effects. They cannot supply an adolescent starting dose merely because alprostadil has been studied in adults. Pediatric pharmacotherapy requires attention to the population actually enrolled, the formulation studied, and whether the proposed use appears in current labeling.

Research on erectile dysfunction in “young men” needs the same careful reading. A frequently cited clinic study found that younger adult men made up a meaningful share of new erectile-dysfunction presentations, and a separate treatment-algorithm study evaluated healthy young men [14][15]. Neither paper establishes Caverject or MUSE dosing for patients ages 12 to 17. A search result or article title containing “young” should never be treated as pediatric dose evidence without checking the enrolled ages and methods.

Risks that matter before alprostadil is considered

The absence of a pediatric dose does not mean the known adult risks disappear. Current Caverject labeling warns about prolonged erection and priapism, penile fibrosis, hypotension, injection-site bleeding in patients taking anticoagulants, needle breakage, and the unstudied safety of combining Caverject with other intracavernosal vasoactive medications [1]. Penile pain is the most common adverse reaction in the adult clinical-trial program [1].

MUSE has route-specific risks, including urethral pain or burning, urethral bleeding or spotting, dizziness, hypotension, and syncope during adult titration studies [3]. The applicator and intraurethral route also require product-specific instruction.

An adolescent evaluation should therefore identify conditions or circumstances that could change risk, including a history of prolonged erections, sickle cell disease or another priapism predisposition, bleeding risk, penile anatomy, cardiovascular symptoms, and concomitant medications. This list is not a self-screening checklist; it illustrates why an online age-based dose is inadequate.

A prolonged erection is time-sensitive

The AUA/SMSNA priapism guideline defines priapism as an erection lasting more than four hours and describes acute ischemic priapism as a medical emergency that can lead to cavernosal fibrosis and erectile dysfunction [8]. It specifically says patients receiving intracavernosal injection teaching should be instructed to return to the office or emergency department for an erection lasting longer than four hours [8].

Do not wait for severe pain before seeking help. Do not take an unprescribed decongestant, inject another drug, or attempt aspiration at home based on an online instruction. A clinician must determine whether the erection is ischemic and choose the appropriate treatment. For an adolescent, a parent or guardian should follow the treating team's emergency plan unless doing so would delay urgent care.

What a specialist visit should clarify

A useful visit should clarify the diagnosis, medication or substance contributors, whether testing is needed, and which cause-directed or noninvasive options come first. If alprostadil is proposed, ask why its off-label use is justified, which exact product and route would be used, where administration and titration would occur, and which symptoms require a same-day call or emergency care. That structured approach reflects the pediatric-urology review and the AAP's focus on individual benefit and the best available evidence [4][5].

What not to do

Do not use a parent's, partner's, or another adult's Caverject, Caverject Impulse, MUSE, bimix, or trimix. Do not transfer a dose between the vial, Impulse device, and urethral system. Do not combine alprostadil with another injected vasoactive medication unless the prescribing specialist explicitly directs it; current Caverject labeling says such combinations have not been systematically studied and are not recommended [1].

Do not increase a dose because the first attempt did not work. In the adult label, the first injections and dose finding occur under medically trained supervision [1]. That safeguard is especially important when no pediatric dosing schedule exists.

Do not buy a compounded injection described only in “units” without a written concentration and ingredient list. Units are a volume marking, not a universal drug dose, and compounded combinations are not interchangeable with FDA-approved Caverject.

How strong is the evidence?

The evidence is strong for what the labels say: pediatric safety and effectiveness are not established for Caverject, and MUSE is not indicated for children [1][3]. The evidence is also clear that adolescent erectile dysfunction deserves a developmentally appropriate evaluation [4] and that an erection lasting more than four hours requires urgent assessment [8].

The evidence is weak for the proposition that a single alprostadil dose table can safely cover everyone ages 12 to 17. No current FDA label supplies such a table. The adult AUA guideline and adult product trials cannot fill that pediatric dose-finding gap [7].

That distinction is important for searchers and clinicians alike. A page can be detailed without pretending the literature is more complete than it is. For adolescents, the most accurate “dosing guide” is a clear explanation that no established pediatric regimen exists, what the adult labels do and do not establish, and which decisions require a pediatric specialist.